mRNA-4157,Pembrolizumab
Moderna,Merck
['melanoma']
first rct to show the benefit of personalised #mrna #cancer #vaccine plus immunotherapy shows the combined treatment cuts risk of recurrence in advanced #melanoma by 44% #aacr23 
CancerWorld explores cancer care from all viewpoints, and offers readers insight into the decisions that shape their professional and personal world.